• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    TMRW Appoints Brian E. Miller, Ph.D., as SVP of Sales

    3/5/21 9:00:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    NEW YORK, March 5, 2021 /PRNewswire/ -- TMRW Life Sciences, Inc. ("TMRW"), the creator of the world's first and only automated technology platform for the management, identification, and storage of frozen eggs and embryos, announces today that Brian E. Miller, PhD, is joining TMRW's senior leadership team as Senior Vice President of Sales.

    In his role, Brian will be responsible for bringing TMRW's innovative technology to fertility clinics in the United States. Brian will also be integral to the ongoing development of new products and services that will expand TMRW's offerings, enabling fertility clinics to further enhance and automate their clinical lab operations.

    A veteran of the fertility industry, Brian has over 25 years of experience at the nexus of science and technology, scaling fertility products and solutions and bringing them to market to improve patient care. Brian has an extensive background in biotech and pharma sales, medical affairs, medical practice operations, business development, government affairs, clinical laboratory and research, and alliance partner management. Brian has a profound understanding of the clinicians and patients who he works with, which has allowed him to foster deep and long-lasting relationships with his clients.

    Brian joins TMRW from CooperSurgical, the fertility, genomics, and women's health division of The Cooper Companies (NYSE: COO), where he led all fertility and genomic solutions and patient advocacy for North America.

    Previously, Brian was Chief Commercial Officer at Recombine, a clinical genetic testing company specializing in carrier screening which was acquired by CooperSurgical in 2016. He also served as Chief Operating Officer at the Fertility Centers of New England.  Earlier in his career, Brian held multiple senior positions at EMD Serono, where he helped lead a medical affairs team and managed all U.S. strategic accounts for endocrinology and fertility sales.  At Organon, as a medical liaison, he supported the science and launch of new products through education.

    Brian began his career as an andrologist at the Hospital of Central Connecticut, and advanced to Associate Director of Clinical Research and reproductive endocrinology and andrology lab supervisor. He completed a Ph.D. from the University of Connecticut.

    Alan Murray, TMRW's Founder and Co-CEO commented: "Brian is one of the best known and most respected executives in the fertility field. Over his two decade career, he has won the trust and admiration of the leading clinicians and innovators in not only the fertility space, but also the many key intersecting disciplines such as genetic testing and lab operations. We could not be more delighted by his arrival to further TMRW's appeal to innovators in the fertility space."

    "TMRW is leading the way in developing how IVF will be practiced in the future," said Brian. "The automation revolution TMRW is leading is already benefiting clinicians and patients alike. I'm excited to join a team of innovators, who, in a short period of time, took an extraordinary vision to bring safety to cryospecimen management and developed a game-changing technology solution that will become the community standard in IVF labs worldwide. I am thrilled to be part of the ongoing innovation which is TMRW's future."

    Brian's appointment comes on the heels of TMRW's commercial launch in February 2021.

    About TMRW Life Sciences, Inc.

    TMRW has created the world's first automated platform designed specifically for cryo-management of eggs and embryos used in IVF. TMRW's RFID-enabled, complete digital chain of custody SaaS technology radically improves upon the error-prone manual and analog methods that have gone unchanged throughout the history of IVF, significantly reducing the chances of implantation mix-ups or loss of eggs and embryos. The TMRW team includes many of the world's most celebrated innovators in fertility, embryology, cryo-management, automation, software development and robotics to name a few of the disciplines involved.  TMRW's co-founders, Joshua Abram, Alan Murray, and Dr. Jeffrey Port, are serial tech and life sciences entrepreneurs. Their immediate prior ventures sold for a combined sum of more than $1 billion. To date, TMRW has raised $50 million. For more information, please visit TMRW.org.

    Media Contact
    Emily Grosser, Dini von Mueffling Communications
    [email protected]
    757-645-5190

    SOURCE TMRW Life Sciences

    Related Links

    https://www.tmrw.org/

    Get the next $COO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    5/30/2025$76.00Overweight → Neutral
    Analyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cooper upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Cooper from Neutral to Outperform and set a new price target of $92.00

    7/22/25 7:47:24 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper upgraded by Needham with a new price target

    Needham upgraded Cooper from Hold to Buy and set a new price target of $94.00

    6/17/25 7:46:56 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Analyst with a new price target

    Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00

    5/30/25 8:39:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Carbone Barbara

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    5/5/25 4:16:23 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Carbone Barbara

    3 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    5/5/25 4:14:05 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kozy William A converted options into 2,857 shares, increasing direct ownership by 10% to 31,149 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/3/25 4:09:38 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Barbara Carbone to Board of Directors

    SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

    4/30/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

    SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

    11/30/23 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperVision Canada Marks Fifth Year of Raising Awareness About Childhood Myopia and Treatment Options

    TORONTO, Aug. 18, 2025 /CNW/ - For the fifth year in a row, CooperVision Canada is investing in educating parents and raising awareness about myopia (aka nearsightedness) in children, emphasizing that it is more than just a blurry vision issue, it is a progressive condition that requires proactive management to help protect long-term eye health and preserve future opportunities for children. MiSight® 1 day contact lenses from CooperVision can help age-appropriate children with myopia reach their full potential. MiSight® 1 day is the first and only FDA approved* soft contact le

    8/18/25 4:16:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies to Participate in the Wells Fargo Healthcare Conference

    SAN RAMON, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025. Al White, President and CEO, will represent the Company in a session scheduled at 3:00 PM ET. The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical.

    8/14/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Third Quarter 2025

    SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

    7/24/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    SEC Filings

    View All

    SEC Form SD filed by The Cooper Companies Inc.

    SD - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/30/25 4:20:18 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by The Cooper Companies Inc.

    10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/30/25 4:19:23 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/29/25 4:31:50 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Release Date for Third Quarter 2025

    SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

    7/24/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Second Quarter 2025 Results

    SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

    5/29/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Second Quarter 2025

     SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

    4/29/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care